Tenaya Therapeutics, Inc. (TNYA) company profile
Close on Nov 17, 2026Market cap $72.38MP/E –Yield –
About Tenaya Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops therapies targeting the underlying drivers of heart disease. Its lead product candidates include TN-201, an adeno-associated virus gene therapy in clinical trials for hypertrophic cardiomyopathy associated with MYBPC3 genetic variants, and TN-401, a gene therapy in clinical trials for arrhythmogenic right ventricular cardiomyopathy associated with PKP2 variants. The company also develops TN-301, a small molecule histone deacetylase 6 inhibitor investigated for heart failure with preserved ejection fraction and other disorders. Its target patient populations comprise individuals affected by rare genetic and prevalent cardiovascular conditions, and it collaborates with pharmaceutical partners.
The company conducts its activities in the United States, with facilities that include office and laboratory space in South San Francisco, California, as well as a manufacturing facility in Union City, California. Tenaya Therapeutics is headquartered in South San Francisco, California.
Summary of the business section of Tenaya Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Tenaya Therapeutics, Inc.
- Headquarters
- South San Francisco, CA
- Address
- 171 Oyster Point Blvd., Suite 500 94080
- Phone
- (415) 865-2066
- Website
- tenayatherapeutics.com
- Employees
- 70, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, San Francisco, California
Stock & identifiers
- Ticker
- TNYA
- Exchange
- Nasdaq
- IPO date
- Jul 30, 2021
- Shares outstanding
- 224M, Jul 30, 2026
- Public float
- $63.10M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1858848
- CUSIP
- 87990A106
- ISIN
- US87990A1060
- FIGI
- BBG00FPMK2S3
- Share class FIGI
- BBG00FPMK2T2
- EIN
- 81-3789973
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Faraz Ali | Chief Executive Officer, Director | 539,782 |
| Whittemore Tingley | Chief Medical Officer | 263,073 |
| Eric J. Hyllengren | Chief Financial Officer | – |
| Tomohiro Higa | SVP, Finance | 118,267 |
| Karah Herdman Parschauer | Director | – |
| R. Sanders Williams | Director | 29,999 |
| Catherine Stehman-Breen | Director | 8,125 |
| June Lee | Director | – |
| Jeffrey T. Walsh | Director | – |
| Deepak Srivastava | Director | 564,101 |
| Amy L. Burroughs | Director | – |
| David V. Goeddel | Director | 49,313,559 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Faraz Ali Chief Executive Officer | $664.17K | $141.92K | $755.51K | $319.28K | $516 | $1.88M | -43% |
| Whittemore (Whit) Tingley Chief Medical Officer | $521.19K | $86.73K | $385.07K | $180.14K | $1.52K | $1.17M | -29% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 30, 2021
- Offer price
- $15.00
- Securities offered
- 12,000,000
- Gross proceeds
- $180.00M
- Exchange
- Nasdaq
- First trading day
- Jul 30, 2021
- First-day close
- $15.35+2.3%
- Lock-up ends (est.)
- Jan 26, 2022
“The initial public offering price is $15.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 70 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 30, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 18, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 30, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 23, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?